Management of Toxicities From Immunotherapy: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up

Ann Oncol. 2017 Jul 1;28(suppl_4):iv119-iv142. doi: 10.1093/annonc/mdx225.

Publication types

  • Practice Guideline

MeSH terms

  • Antibodies, Monoclonal / adverse effects*
  • Antibodies, Monoclonal, Humanized / adverse effects
  • Antineoplastic Agents, Immunological / adverse effects*
  • Drug-Related Side Effects and Adverse Reactions / diagnosis
  • Drug-Related Side Effects and Adverse Reactions / etiology
  • Drug-Related Side Effects and Adverse Reactions / immunology
  • Drug-Related Side Effects and Adverse Reactions / therapy*
  • Follow-Up Studies
  • Humans
  • Ipilimumab / adverse effects
  • Medical Oncology / standards*
  • Neoplasms / drug therapy
  • Neoplasms / immunology
  • Nivolumab

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents, Immunological
  • Ipilimumab
  • Nivolumab
  • pembrolizumab